Concepts (137)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Polycythemia | 1 | 2018 | 19 | 0.72 | Why? |
| Endothelium, Vascular | 3 | 2021 | 1751 | 0.57 | Why? |
| Anticoagulants | 8 | 2021 | 9563 | 0.49 | Why? |
| Aspirin | 1 | 2021 | 1043 | 0.48 | Why? |
| Vascular Diseases | 2 | 2020 | 846 | 0.47 | Why? |
| Venous Thromboembolism | 6 | 2021 | 4273 | 0.45 | Why? |
| Platelet Aggregation Inhibitors | 2 | 2021 | 1671 | 0.43 | Why? |
| Blood Coagulation Disorders | 3 | 2021 | 2040 | 0.42 | Why? |
| Smoking Cessation | 1 | 2018 | 826 | 0.38 | Why? |
| Teaching | 1 | 2018 | 1208 | 0.36 | Why? |
| Physician-Patient Relations | 1 | 2018 | 1266 | 0.34 | Why? |
| Motivation | 1 | 2018 | 1640 | 0.33 | Why? |
| Hematology | 2 | 2021 | 649 | 0.25 | Why? |
| Matrix Metalloproteinase 7 | 1 | 2021 | 21 | 0.23 | Why? |
| Hepatocyte Growth Factor | 1 | 2021 | 71 | 0.22 | Why? |
| Neutrophil Activation | 2 | 2021 | 510 | 0.22 | Why? |
| Blood Platelet Disorders | 1 | 2020 | 44 | 0.21 | Why? |
| Lipocalin-2 | 1 | 2021 | 156 | 0.21 | Why? |
| Health Behavior | 1 | 2018 | 4449 | 0.19 | Why? |
| Training Support | 1 | 2018 | 131 | 0.16 | Why? |
| Hospital Mortality | 1 | 2021 | 22087 | 0.16 | Why? |
| Nephrotic Syndrome | 1 | 2018 | 146 | 0.15 | Why? |
| Respiratory Function Tests | 1 | 2021 | 1755 | 0.13 | Why? |
| Lower Extremity | 1 | 2018 | 593 | 0.12 | Why? |
| Internal Medicine | 1 | 2018 | 557 | 0.12 | Why? |
| Peripheral Arterial Disease | 1 | 2018 | 471 | 0.12 | Why? |
| Venous Thrombosis | 2 | 2017 | 2739 | 0.11 | Why? |
| Pulmonary Fibrosis | 1 | 2021 | 1068 | 0.11 | Why? |
| Administration, Oral | 1 | 2018 | 2340 | 0.11 | Why? |
| Endothelial Cells | 1 | 2021 | 2048 | 0.10 | Why? |
| Ischemia | 1 | 2018 | 901 | 0.10 | Why? |
| Inflammation Mediators | 1 | 2021 | 2654 | 0.10 | Why? |
| Societies, Medical | 3 | 2021 | 6907 | 0.09 | Why? |
| Thrombosis | 2 | 2020 | 7504 | 0.08 | Why? |
| Hemorrhage | 1 | 2018 | 3013 | 0.08 | Why? |
| Brain Ischemia | 1 | 2021 | 2813 | 0.07 | Why? |
| Liver Diseases | 1 | 2021 | 2698 | 0.07 | Why? |
| Follow-Up Studies | 2 | 2020 | 17020 | 0.07 | Why? |
| Middle Aged | 10 | 2021 | 270681 | 0.07 | Why? |
| Humans | 21 | 2021 | 930598 | 0.06 | Why? |
| Interleukin-6 | 1 | 2021 | 7522 | 0.06 | Why? |
| Prognosis | 3 | 2021 | 32490 | 0.06 | Why? |
| Critical Illness | 3 | 2021 | 17281 | 0.06 | Why? |
| Tertiary Care Centers | 2 | 2017 | 8248 | 0.06 | Why? |
| Medical Oncology | 1 | 2018 | 3826 | 0.06 | Why? |
| Endothelium-Dependent Relaxing Factors | 1 | 2020 | 24 | 0.06 | Why? |
| Aged | 8 | 2021 | 215776 | 0.06 | Why? |
| Pulmonary Embolism | 2 | 2017 | 4775 | 0.05 | Why? |
| Inflammation | 2 | 2021 | 13255 | 0.05 | Why? |
| Iloprost | 1 | 2020 | 38 | 0.05 | Why? |
| Epoprostenol | 1 | 2020 | 41 | 0.05 | Why? |
| Female | 9 | 2021 | 380317 | 0.05 | Why? |
| Retrospective Studies | 6 | 2021 | 105322 | 0.05 | Why? |
| Biomarkers | 2 | 2021 | 23361 | 0.05 | Why? |
| Aged, 80 and over | 5 | 2021 | 88759 | 0.05 | Why? |
| STAT3 Transcription Factor | 1 | 2021 | 268 | 0.05 | Why? |
| Janus Kinase 1 | 1 | 2021 | 254 | 0.05 | Why? |
| Betacoronavirus | 2 | 2020 | 204454 | 0.05 | Why? |
| Fasciotomy | 1 | 2018 | 23 | 0.05 | Why? |
| Incidence | 1 | 2021 | 25622 | 0.05 | Why? |
| Ankle Brachial Index | 1 | 2018 | 53 | 0.05 | Why? |
| Antibodies, Monoclonal, Humanized | 1 | 2020 | 9335 | 0.04 | Why? |
| Male | 9 | 2021 | 367725 | 0.04 | Why? |
| Adult | 6 | 2021 | 244371 | 0.04 | Why? |
| Evidence-Based Medicine | 2 | 2021 | 3228 | 0.04 | Why? |
| Hemostatic Disorders | 1 | 2017 | 20 | 0.04 | Why? |
| Vasodilator Agents | 1 | 2020 | 344 | 0.04 | Why? |
| Immobilization | 1 | 2017 | 74 | 0.04 | Why? |
| Ultrasonography, Doppler, Duplex | 1 | 2018 | 168 | 0.04 | Why? |
| Immunoglobulin G | 1 | 2021 | 21571 | 0.04 | Why? |
| Thrombotic Microangiopathies | 1 | 2020 | 335 | 0.04 | Why? |
| Guidelines as Topic | 2 | 2021 | 2844 | 0.04 | Why? |
| Vena Cava Filters | 1 | 2017 | 89 | 0.04 | Why? |
| Nitriles | 1 | 2021 | 1053 | 0.04 | Why? |
| Cross-Sectional Studies | 2 | 2021 | 53120 | 0.04 | Why? |
| Connecticut | 1 | 2017 | 547 | 0.04 | Why? |
| Amputation | 1 | 2018 | 331 | 0.04 | Why? |
| Fibrinogen | 1 | 2021 | 1048 | 0.04 | Why? |
| Time Factors | 4 | 2021 | 31397 | 0.04 | Why? |
| von Willebrand Factor | 1 | 2021 | 668 | 0.04 | Why? |
| Pneumonia, Viral | 2 | 2020 | 243684 | 0.04 | Why? |
| Coronavirus Infections | 2 | 2020 | 253789 | 0.03 | Why? |
| Chi-Square Distribution | 1 | 2017 | 961 | 0.03 | Why? |
| Administration, Inhalation | 1 | 2020 | 1647 | 0.03 | Why? |
| Administration, Intravenous | 1 | 2018 | 1115 | 0.03 | Why? |
| Antibodies, Neutralizing | 1 | 2021 | 25288 | 0.03 | Why? |
| Enoxaparin | 1 | 2021 | 1064 | 0.03 | Why? |
| Nitric Oxide | 1 | 2020 | 769 | 0.03 | Why? |
| Intensive Care Units | 1 | 2020 | 29594 | 0.03 | Why? |
| Pyrimidines | 1 | 2021 | 1557 | 0.03 | Why? |
| Neoplasms | 2 | 2018 | 17251 | 0.03 | Why? |
| Kinetics | 1 | 2021 | 3238 | 0.03 | Why? |
| Young Adult | 2 | 2020 | 93724 | 0.03 | Why? |
| Severity of Illness Index | 4 | 2021 | 48226 | 0.03 | Why? |
| Treatment Outcome | 4 | 2020 | 51732 | 0.03 | Why? |
| Drug Administration Schedule | 1 | 2018 | 2324 | 0.03 | Why? |
| Recovery of Function | 1 | 2021 | 2461 | 0.03 | Why? |
| Spike Glycoprotein, Coronavirus | 1 | 2021 | 37182 | 0.03 | Why? |
| Pyrazoles | 1 | 2021 | 1791 | 0.03 | Why? |
| Patient Care | 1 | 2021 | 1664 | 0.03 | Why? |
| Hemodynamics | 1 | 2017 | 1562 | 0.02 | Why? |
| Carrier State | 1 | 2021 | 2100 | 0.02 | Why? |
| Dose-Response Relationship, Drug | 1 | 2018 | 3776 | 0.02 | Why? |
| Medication Adherence | 1 | 2018 | 1270 | 0.02 | Why? |
| Antibodies, Viral | 1 | 2021 | 51949 | 0.02 | Why? |
| United States | 3 | 2021 | 46150 | 0.02 | Why? |
| Dyspnea | 1 | 2021 | 3847 | 0.02 | Why? |
| Cough | 1 | 2021 | 4891 | 0.02 | Why? |
| Recurrence | 1 | 2017 | 3675 | 0.02 | Why? |
| Multivariate Analysis | 1 | 2017 | 5440 | 0.02 | Why? |
| Immunity, Humoral | 1 | 2021 | 4849 | 0.02 | Why? |
| Thrombolytic Therapy | 1 | 2018 | 2218 | 0.02 | Why? |
| Survival Rate | 1 | 2020 | 9206 | 0.02 | Why? |
| Risk Factors | 3 | 2021 | 71621 | 0.02 | Why? |
| Acute Disease | 1 | 2018 | 6029 | 0.02 | Why? |
| Heparin | 1 | 2018 | 2600 | 0.02 | Why? |
| Survival Analysis | 1 | 2018 | 7592 | 0.02 | Why? |
| Drug Therapy, Combination | 1 | 2018 | 7268 | 0.02 | Why? |
| Machine Learning | 1 | 2021 | 4395 | 0.02 | Why? |
| Signal Transduction | 1 | 2021 | 7207 | 0.02 | Why? |
| Patient Selection | 1 | 2018 | 4560 | 0.02 | Why? |
| Length of Stay | 1 | 2021 | 11042 | 0.02 | Why? |
| Algorithms | 1 | 2020 | 7346 | 0.02 | Why? |
| Glucocorticoids | 1 | 2018 | 4431 | 0.01 | Why? |
| Obesity | 1 | 2021 | 7388 | 0.01 | Why? |
| Systemic Inflammatory Response Syndrome | 1 | 2020 | 6653 | 0.01 | Why? |
| Randomized Controlled Trials as Topic | 1 | 2018 | 10649 | 0.01 | Why? |
| Hospitalization | 2 | 2021 | 54280 | 0.01 | Why? |
| Cytokines | 1 | 2021 | 15010 | 0.01 | Why? |
| Pandemics | 3 | 2021 | 389249 | 0.01 | Why? |
| Cohort Studies | 1 | 2021 | 36005 | 0.01 | Why? |
| Internship and Residency | 1 | 2018 | 4987 | 0.01 | Why? |
| Age Factors | 1 | 2017 | 21039 | 0.01 | Why? |
| Prevalence | 1 | 2017 | 25773 | 0.01 | Why? |
| Respiration, Artificial | 1 | 2020 | 22116 | 0.01 | Why? |
| Lung | 1 | 2021 | 31049 | 0.01 | Why? |
| Child | 1 | 2018 | 70012 | 0.01 | Why? |
Lee's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(137)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(223)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_